Eli Lilly leader speaks to antibody treatment aimed at lessening COVID-19 symptoms

Central Illinois Newsday

PEORIA, Ill. (WMBD) — While COVID-19 vaccination is ramping up in the US, there’s still a critical need for treatments to help people who get infected with the virus.

Experts say getting treated soon after diagnosis gives people the best odds of avoiding severe disease or hospitalization.

Janelle Sabo, Global Therapeutics Platform Leader at Eli Lilly and Company, speaks to the antibody treatments called Bamlanivimab and Etesevimab.

Both are investigational medicines used to treat mild to moderate symptoms of COVID-19 in adults and adolescents (12 years of age and older who weigh at least 88 pounds (40 kg)), and who are at
high risk for developing severe COVID-19 symptoms or the need for hospitalization.

How can I learn more?

Latest Headlines

Stay Connected

Copyright 2021 Nexstar Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Latest Local News

More Local News